Climate Change Data

Environmental Metrics

ESG Focus Areas

• Health and Safety
• Environment
• Employees
• Community
• Ethical Standards
• Diversity

Environmental Achievements

• Not disclosed

Social Achievements

• Commitment to workplace diversity including gender, age, ethnicity and cultural background.
• Not disclosed

Governance Achievements

• Established audit, remuneration and nomination committees.
• Adopted a code for Directors’ dealings based on the Model Code contained in the Listing Rules.

Climate Goals & Targets

Environmental Challenges

• The Group’s business is relatively undeveloped and at an early stage with no commercial sales.
• Development of clinical products is inherently uncertain with high failure rates and can be expensive and time-consuming.
• Reliance on key personnel.
• Costs of commercialisation could be significant.
• Uncertainty in clinical studies and timelines.
• Research and development risk.
• Intellectual property infringement risk.
• Intellectual property control.
• Environmental and other regulatory requirements.
• Financing through further raising of new equity capital.
• Market conditions and competition.
• Pandemic and business disruption risk.

Mitigation Strategies

• Careful planning of expenditure with rolling cash flow forecasts and tight financial control.
• Collaborative cost sharing approach with business partners.
• Contractual arrangements with key personnel including non-compete restrictions.
• Proactive approach to filing patents.
• Diligent maintenance and protection of patents and licenses.
• Monitoring of market conditions.
• Monitoring of environmental and regulatory compliance.
• Successful raising of new equity capital.
• New laboratory premises to reduce outsourcing costs and enable in-house manufacturing.

Supply Chain Management

Supplier Audits: Not disclosed

Responsible Procurement

• Not disclosed

Climate-Related Risks & Opportunities

Physical Risks

• Not disclosed

Transition Risks

• Not disclosed

Opportunities

• Not disclosed

Reporting Standards

Frameworks Used: Null

Certifications: Null

Third-party Assurance: Not disclosed

UN Sustainable Development Goals

• Not disclosed

Not disclosed

Sustainable Products & Innovation

• HEMO-CAR-T
• CDX antibody
• CBR platform
• Hu-PHEC cell therapy

Awards & Recognition

• Not disclosed

Environmental Metrics

ESG Focus Areas

• Health and Safety
• Environment
• Employees
• Community
• Ethical Standards

Environmental Achievements

• Minimised business travel, using internet-based communication tools; policy of preferring low-energy consumption devices and switching them off when not in use; used less than 40,000kWh of energy in the UK during 2022.

Social Achievements

• Opened a new custom-designed laboratory in New York City; appointed Dr Koen van Besien as Medical Director and Stuart Tinch as Director of Quality; committed to workplace diversity.

Governance Achievements

• Established audit, remuneration, and nomination committees; adopted a code for Directors’ dealings based on the Model Code; high level of attendance and participation of Directors at Board and committee meetings.

Climate Goals & Targets

Environmental Challenges

• The Group’s business is relatively undeveloped; development of clinical products is inherently uncertain with high failure rates; reliance on key personnel; costs of commercialisation; clinical studies and timelines risk; research and development risk; intellectual property infringement; intellectual property control; environmental and other regulatory requirements; financing; market conditions; political and country risk.

Mitigation Strategies

• Careful planning of expenditure with rolling cash flow forecasts and tight financial control; collaborative cost sharing approach with business partners; avoiding long-term commitments; proactive approach to filing patents; diligent maintenance and protection of patents and licenses; embedding climate-related risk management systems into overall internal control systems; monitoring energy use; adopting SASB recommended disclosures in the next 2-3 years; monitoring matters and seeking advice to mitigate risks arising from Brexit or other international trade changes; risk assessment before signing up to any commitments; continuous dialogue with shareholders; understanding and engaging with all key stakeholder groups.

Supply Chain Management

Supplier Audits: Not disclosed

Responsible Procurement

• Not disclosed

Climate-Related Risks & Opportunities

Physical Risks

• Not disclosed

Transition Risks

• Not disclosed

Opportunities

• Not disclosed

Reporting Standards

Frameworks Used: TCFD

Certifications: Null

Third-party Assurance: Not disclosed

UN Sustainable Development Goals

• Not disclosed

Not disclosed

Sustainable Products & Innovation

• HEMO-CAR-T, CDX, CBR platform, Hu-PHEC cell therapy

Awards & Recognition

• Not disclosed

Environmental Metrics

ESG Focus Areas

• Health and Safety
• Environment
• Employees
• Community
• Ethical Standards

Environmental Achievements

• Minimised business travel, using internet-based communication tools; policy of preferring low energy consumption devices and switching them off when not in use.

Social Achievements

• Commitment to workplace diversity (gender, age, ethnicity, cultural background); implemented Diversity Policy.

Governance Achievements

• Established audit, remuneration, and nomination committees; adopted a code for Directors’ dealings based on the Model Code; high level of attendance and participation of Directors at Board and committee meetings.

Climate Goals & Targets

Environmental Challenges

• FDA imposed a clinical hold on HEMO-CAR-T program due to safety concerns; successively lower fundraising prices in the UK market; inherent uncertainties in clinical product development; reliance on key personnel; high costs of commercialisation; risks associated with clinical studies and timelines; research and development risks; intellectual property infringement risks; intellectual property control; environmental and regulatory requirements; financing challenges; market competition; political and country risks.

Mitigation Strategies

• Scientific team worked to resolve FDA concerns and remanufacture CAR-T components; strategic investment from Prevail Partners; careful expenditure planning with rolling cash flow forecasts and tight financial control; collaborative cost sharing with business partners; avoiding long-term commitments; proactive approach to filing patents; diligent maintenance and protection of patents and licenses; monitoring product development through pre-clinical results; humanised mouse model for testing; active engagement with stakeholders; monitoring market conditions; monitoring international trade regulations.

Supply Chain Management

Supplier Audits: Not disclosed

Responsible Procurement

• Not disclosed

Climate-Related Risks & Opportunities

Physical Risks

• Not disclosed

Transition Risks

• Not disclosed

Opportunities

• Not disclosed

Reporting Standards

Frameworks Used: TCFD

Certifications: Null

Third-party Assurance: Not disclosed

UN Sustainable Development Goals

• Not disclosed

Not disclosed

Sustainable Products & Innovation

• HEMO-CAR-T, CDX antibodies, CBR platform

Awards & Recognition

• Not disclosed